Lopinavir and Ritonavir
- Generic Name
- Lopinavir and Ritonavir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用于与其它抗逆转录病毒药物联合用药，治疗HIV感染。
- Associated Conditions
- -
- Associated Therapies
- -
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2023-03-01
- Target Recruit Count
- 118
- Registration Number
- NCT04328285
- Locations
- 🇫🇷
CHU de Rouen, Rouen, France
🇫🇷CHU de Bordeaux, Bordeaux, France
🇫🇷CHU de Rennes, Rennes, France
Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
- Target Recruit Count
- 228
- Registration Number
- NCT01166477
- Locations
- 🇪🇸
Hospital Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸Hospital Severo Ochoa, Leganés, Madrid, Spain
🇪🇸Hospital Virgen de la Cinta, Tortosa, Tarragona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath